Abstract 5063
Background
With this study, we aimed to present the impact of malnutrition on the tolerability and efficacy ofchemotheraphy, and overall survival on metastatic gastric cancer (mGC) patients.
Methods
In this prospective multicenter study, we collected demographic, oncological and nutritional data for our mGC patients. Nutritional status was assessed with the Nutritional Risk Index (NRI), Body Mass Index (BMI) and clinical weight loss percentage with 21-day period during two chemotherapy cycles. NRI were calculated with formula as following; 1.519 x serum albumin level (g/L) + 41.7 x current weight/basic weight. Patients were calssified as having ‘no’ (NRI >97.5), ‘moderate’ (97.5 ≥ NRI ≥83.5) or ‘severe’ (NRI <83.5) malnutrition. Drug-induced toxicities were evaluated using National Cancer Institute CTCAE version 4.0 and treatment responses were evaluated using RECIST Criteria 1.1.
Results
116 mGC patients enrolled. Median age was 60 years. Primary location of tumor was non-antrum/antrum with 60/40% and 24% of patients had experienced primary tumor resection. WHO performance status of patients was 0-1 for 98%. All treatments were first-line setting. 41% of patients dead of during follow up period (Median: 138 days, Range: 21-378). Malnurition diagnosed in 68 % of the patients and was severe in 32%. Moderate/severe malnutrution was associated with more treatment toxicity (≥ grade 2 cytopenia, nausea/vomiting, diarrhea, neuropathy; p < 0.05 for all parameters). Moderate/severe malnutrution was not associated with chemoteraphy responses (p = 0.215). Malnutritional level was associated with significantly reduced overall survival (OS), none, moderately or severe malnourished groups, with 350 days (95% CI, 176.0 - 524.0), 210 (95 %CI, 166.3 - 253.7), 74 (95% CI, 20.7 - 111.0) respectively (p = 0.025). Severe malnutition was associated with shorter OS (74 vs. 237 days in non/moderatery, p = 0.007).
Conclusions
In mGC patients, moderate/severe malnutrition is associated with worse non-hematological chemotherapy toxicities. Malnutrition level and severe malnutrition is also associated reduced overall survival.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2078 - Comprehensive genomic profiling and clinical outcomes in patients (pts) with fibroblast growth factor receptor rearrangement-positive (FGFR2+) cholangiocarcinoma (CCA) treated with pemigatinib in the fight-202 trial
Presenter: Antoine Hollebecque
Session: Poster Display session 2
Resources:
Abstract
3879 - Efficacy of derazantinib (DZB) in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) expressing FGFR2-fusion or FGFR2 mutations/amplifications
Presenter: Michele Droz Dit Busset
Session: Poster Display session 2
Resources:
Abstract
4679 - It’s Not Only About Weight Loss: Tackling Pancreatic Cancer-Associated Cachexia
Presenter: Ana Leonor Matos
Session: Poster Display session 2
Resources:
Abstract
2276 - Frequency and clinicopathological characteristics of biliary tract carcinomas harboring the FGFR2-fusion gene: a prospective observational study (PRELUDE study)
Presenter: Masafumi Ikeda
Session: Poster Display session 2
Resources:
Abstract
2773 - Post-hoc analyses of a subgroup of patients with advanced biliary tract cancer (BTC) who crossed over to treatment with etoposide toniribate (EDO-S7.1) in a randomized Phase II study
Presenter: Ulrich-Frank Pape
Session: Poster Display session 2
Resources:
Abstract
4479 - Capecitabine +Best supportive care (BSC) or Erlotinib +BSC has Overall survival (OS) benefit over BSC alone in unresectable/metastatic Gall bladder cancer(GBC) patients with ECOG PS-III. Results from a phase II Randomised controlled trial (RCT)
Presenter: Babita Kataria
Session: Poster Display session 2
Resources:
Abstract
4843 - FGFR2 fusions and its effect of patient (pt) outcomes in intrahepatic cholangiocarcinoma (iCCA)
Presenter: Daniel Almquist
Session: Poster Display session 2
Resources:
Abstract
2324 - The Clinical Outcomes of Systemic Chemotherapy in Patients with Unresectable or Metastatic Combined Hepatocellular-cholangiocarcinoma (HCC-CCA): Retrospective Study of 120 Patients
Presenter: Eojin Kim
Session: Poster Display session 2
Resources:
Abstract
3678 - High PD-L1 expression is associated with treatment response to pembrolizumab in patients with advanced biliary tract cancer.
Presenter: Gilhyang Kim
Session: Poster Display session 2
Resources:
Abstract
3901 - Genomic profiling in Chinese biliary tract cancer patients with PI3K/AKT/mTOR pathway and RAS gene mutations
Presenter: Jingyu Cao
Session: Poster Display session 2
Resources:
Abstract